553 related articles for article (PubMed ID: 28139291)
1. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
2. [PDE-5 inhibitors: patients preferences].
Efremov EA; Kasatonova EV; Melnik YI; Nikushina AA
Urologiia; 2017 Jul; (3):120-126. PubMed ID: 28845950
[TBL] [Abstract][Full Text] [Related]
3. [Dosage forms of sildenafil in the management of erectile dysfunction].
Grigoryan VA; Gazimiev MA; Demidko YL; Baiduvaliev AM
Urologiia; 2018 Mar; (1):159-162. PubMed ID: 29634153
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
5. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film.
Cocci A; Capece M; Cito G; Russo GI; Falcone M; Timpano M; Rizzo M; Della Camera PA; Morselli S; Campi R; Sessa F; Cacciamani G; Minervini A; Gacci M; Mirone V; Morelli G; Mondaini N; Polloni G; Serni S; Natali A
J Sex Med; 2017 Dec; 14(12):1606-1611. PubMed ID: 29153580
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers.
Radicioni M; Castiglioni C; Giori A; Cupone I; Frangione V; Rovati S
Drug Des Devel Ther; 2017; 11():1183-1192. PubMed ID: 28442892
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis.
Xiao Y; Wang J; Luo H
Cochrane Database Syst Rev; 2012 Apr; (4):CD009427. PubMed ID: 22513975
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects.
Lv Y; Luo BY; LaBadie RR; Zhu H; Feng Y; Ernst C; Crownover PH; Liang Y; Zhao Q
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):573-581. PubMed ID: 32463593
[TBL] [Abstract][Full Text] [Related]
12. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
[TBL] [Abstract][Full Text] [Related]
13. The management of erectile dysfunction: innovations and future perspectives.
Leonardi R; Alemanni M
Arch Ital Urol Androl; 2011 Mar; 83(1):60-2. PubMed ID: 21585174
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
15. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects.
Damle B; Duczynski G; Jeffers BW; Crownover P; Coupe A; LaBadie RR
Clin Ther; 2014 Feb; 36(2):236-44. PubMed ID: 24447534
[TBL] [Abstract][Full Text] [Related]
17. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.
Sperling H; Debruyne F; Boermans A; Beneke M; Ulbrich E; Ewald S
J Sex Med; 2010 Apr; 7(4 Pt 1):1497-507. PubMed ID: 20233275
[TBL] [Abstract][Full Text] [Related]
18. Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil.
Jannini EA; Droupy S
Sex Med; 2019 Mar; 7(1):1-10. PubMed ID: 30522978
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation.
Lasaponara F; Sedigh O; Pasquale G; Bosio A; Rolle L; Ceruti C; Timpano M; Negro CL; Paradiso M; Abbona A; Segoloni GP; Fontana D
J Sex Med; 2013 Nov; 10(11):2798-814. PubMed ID: 23346948
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials.
Sperling H; Gittelman M; Norenberg C; Ulbrich E; Ewald S
J Sex Med; 2011 Jan; 8(1):261-71. PubMed ID: 20807322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
